Biocon Receives FDA Approval for Weight Management Drug Liraglutide in United States
Biocon Receives FDA Approval for Weight Management Drug Liraglutide in United States is drawing significant interest across the industry.
Biocon Limited received U.S. FDA approval for Liraglutide Injection (gSaxenda®) for chronic weight management, targeting a US $127 million market opportunity. The once-daily injection is indicated as adjunct therapy to diet and exercise for weight management. CEO Siddharth Mittal highlighted this as a defining milestone validating the company's scientific capabilities and commitment to affordable treatment access.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Why India beating Vietnam is crucial for FIFA World Cup qualification hopes
- Over a billion fear losing land and homes within five years
- How to watch PSG-Monaco Champion’s League match livestream online
- Waldorf Astoria's Chinese Owners Plan to Sell Iconic NYC Hotel, WSJ Reports
Source: Original →